This report was first published by Endpoints News. To see the original version, click here
Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
The move raises questions about whether the drug, called emugrobart, can succeed in its other trials, which are testing its ability to preserve muscle when combined with obesity meds, and as a monotherapy in diabetes.
您已阅读14%（516字），剩余86%（3218字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。